Talazoparib with or without enzalutamide for prostate cancer after prior treatment
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic prostate cancer that is resistant to hormone therapy (castration-resistant).
- You have a genetic mutation in one of the listed genes such as BRCA1, BRCA2, ATM, or others, shown by a blood or tumor test.
- Your cancer has progressed during or after treatment with abiraterone or darolutamide.
- You can swallow pills whole and are willing to be randomly assigned to either talazoparib alone or with enzalutamide.
- You have not had certain prior treatments, such as a PARP inhibitor or platinum chemotherapy, and you do not have other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
This trial tests a combination of two drugs, talazoparib and enzalutamide, in men with advanced prostate cancer that has progressed after previous treatment with a hormone therapy called an AR inhibitor. It aims to see if this combination can help control the cancer and delay further progression.
This expanded access program provides the experimental drug talazoparib (given in combination with enzalutamide) to patients with newly diagnosed metastatic prostate cancer that has become castrate-resistant (no longer responding to hormone therapy). The goal is to make this treatment available before it is formally approved.
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.